As of April 2026

Pipeline Development Status (Clinical Stage)

<Glaucoma and ocular hypertension area>

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
tafluprost / timolol maleate	STN1011101 / DE-111A	Glaucoma / Ocular hypertension	Co-development with AGC	China						Aug-2025
A fixed dose combination drug of a prostaglandin $F_{2\alpha}$ derivative and a beta-adrenergic receptor blocker. Launched in Japan in November 2014. Launched successively in European countries since January 2015. Launched successively in Asian countries since April 2016. Launched in China in August 2025.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
omidenepag isopropyl	STN1011702	Glaucoma/ Ocular hypertension	Co-development with UBE Corporation	China						
A unit dose, preservative free eye drop, EP2 receptor agonist with a new mechanism of action, sold in Japan and Asia. Conducting Phase 3 in China from November 2024.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
sepetaprost	STN1012600 / DE-126	Glaucoma / Ocular hypertension	ONO PHARMACEUTICAL	U.S.						
				Japan						Oct-2025
				Europe	(Exploratory study)					
A bicyclic prostaglandin derivative with a mode of action that is an agonist for FP and EP3 receptors for the treatment of glaucoma and ocular hypertension. Completed an additional Phase 2 in the U.S. in December 2021. Launched in Japan in October 2025. Completed Phase 2 (exploratory study) in Europe.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
latanoprost	STN1013001 / DE-130A (Catioprost)	Glaucoma / Ocular hypertension	Original	Europe						Aug-2024
				Asia					Nov-2024	
An ophthalmic emulsion of a prostaglandin $F_{2\alpha}$ derivative, for the treatment of glaucoma and ocular hypertension. Filed for marketing approval in Asia in November 2024. Launched in European countries including Spain in August 2024.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
netarsudil mesylate	STN1013900 / AR-13324	Glaucoma / Ocular hypertension	Alcon Inc.	Japan				Jul-2025		
				Europe						Feb-2023
				Asia						Nov-2024
A ROCK (Rho-associated kinase) inhibitor. Developed and sold by Alcon Inc. in the U.S.. Filed as a ROCK/NET (norepinephrine transporter) inhibitor for manufacturing and marketing approval in Japan in July 2025. Received marketing approval in Europe and has been launched in Sweden and other countries from February 2023. Successively received marketing approval in Asian countries and launched in South Korea in November 2024.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
netarsudil mesylate / latanoprost	STN1014000 / PG-324	Glaucoma / Ocular hypertension	Alcon Inc.	Europe						Jan-2023
				Asia						Mar-2025
A fixed dose combination drug of a ROCK (Rho-associated kinase) inhibitor and a prostaglandin $F_{2\alpha}$ derivative. Developed and sold by Alcon Inc. in the U.S.. Received marketing approval in Europe and has been launched in Germany and other countries from January 2023. Received marketing approval successively in Asian countries and launched in Singapore in March 2025.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
netarsudil mesylate / latanoprost	STN1014003	Glaucoma / Ocular hypertension	Alcon Inc.	Japan						
A fixed dose combination drug of a ROCK (Rho-associated kinase) inhibitor and a prostaglandin $F_{2\alpha}$ derivative. Developed and sold by Alcon Inc. in the U.S.. Uses a different container from that of STN1014000. Conducting Phase 3 in Japan from February 2025.										

<Keratoconjunctival disease area including dry eye >

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
ciclosporin	STN1007603 / DE-076C	Vernal keratoconjunctivitis	Original	China						Dec-2025
An ophthalmic emulsion which improves vernal keratoconjunctivitis by immunosuppressive effect. Cationic emulsion technology has enhanced ocular tissue penetration. Launched successively in European countries since October 2018. Launched successively in Asian countries after receiving approval for an indication expansion for *Ikervis* in August 2019. Launched in China in December 2025.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
olodaterol hydrochloride	STN1014100	Dry eye	Boehringer Ingelheim	Japan		(Phase 2b)				
β_2 receptor agonist. Started Phase 2b in Japan in May 2025.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
olodaterol hydrochloride	STN1014101	Allergic conjunctivitis	Boehringer Ingelheim	Japan	(Phase 1/2a)					
β_2 receptor agonist. Started Phase 1/2a in Japan in March 2026.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
epinastine hydrochloride	STN1011402	Allergic conjunctivitis	Nippon Boehringer Ingelheim	Japan					May-2024	
				China						
				Asia	Withdrawal of filing for marketing approval in South Korea					
A histamine H_1 receptor antagonist with mediator release inhibitor function, as a treatment for allergic conjunctivitis. Ophthalmic eyelid cream. Launched in Japan in May 2024. Started Phase 3 in China in January 2026. In Asia, withdrew filing for marketing approval in South Korea in March 2026.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
epinastine hydrochloride	STN1011403	Allergic conjunctivitis	Boehringer Ingelheim	China				Mar-2025		
A histamine H_1 receptor antagonist with mediator release inhibitor function, as a treatment for allergic conjunctivitis. High dose formulation to instill twice a day. Filed for marketing approval in China in March 2025.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
nintedanib	STN1014200 / CBT-001	Pterygium	Cloudbreak Pharma Inc.	Japan	(Phase 2b)					
A multi-kinase inhibitor which suppresses angiogenesis and fibrosis. Started Phase 2b in Japan in November 2025.										

< Refractive disorder>

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
atropine sulfate	STN1012700 / DE-127	Myopia	Singapore Health Services, Nanyang Technological University	Japan					Apr-2025	
				China			(Phase 2/3)			
				Asia				July-2025		
Non-selective muscarinic antagonist which reduces the progression of juvenile myopia. Launched in Japan in April 2025. Conducting Phase 2/3 in China from June 2022. Filed for marketing approval in Asia in July 2025.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
atropine sulfate	STN1012701 / SYD-101	Myopia	Sydnexis Inc.	Europe					July-2025	
Non-selective muscarinic antagonist which reduces the progression of juvenile myopia. In Europe, launched in Germany in July 2025.										

< Retinal diseases area >

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
eflimrufusp alfa	STN1014300 / RC28-E	Diabetic macular edema	RemeGen Co., Ltd.	China				Sep-2025		
Dual decoy receptor IgG1 Fc-fusion protein drug simultaneously blocks both VEGF-A and FGF-2. RemeGen Co., Ltd., the licensor, filed for marketing approval in China in September 2025.										

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
eflimrufusp alfa	STN1014301 / RC28-E	Wet age-related macular degeneration	RemeGen Co., Ltd.	China						
Dual decoy receptor IgG1 Fc-fusion protein drug simultaneously blocks both VEGF-A and FGF-2. RemeGen Co., Ltd., the licensor, is conducting Phase 3 trial in China.										

<Others>

Generic name	Dev. code	Indication	Original/Licensor	Region	P1	P2	P3	Filed	Approved	Launched
oxymetazoline hydrochloride	STN1013800	Ptosis	RVL Pharmaceuticals	Japan					Dec-2025	
				Europe						
				China						
A direct-acting alpha adrenergic receptor agonist. Developed and sold by RVL Pharmaceuticals in the U.S.. Received manufacturing and marketing approval in Japan in December 2025. Conducting Phase 3 in Europe from December 2024. Conducting Phase 3 in China from October 2024.										

Changes from Q3 FY2025 (February 5, 2026)

Dev. Code	Changes
STN1014101	Started Phase 1/2a in Japan in March 2026.
STN1011402	In Asia, withdrew filing for marketing approval in South Korea in March 2026.

※ The development of STN1010904 (generic name: sirolimus) was discontinued following the review of Phase 2a data.
(*The development code (STN1010904) was due to be assigned to the product when Santen obtains an exclusive license upon completion of Phase 2 clinical trial)

※ The development of STN1010905 (generic name: sirolimus) was discontinued following the review of additional Phase 2a data.